Aberrant expression of δ-like ligand 4 contributes significantly to axillary lymph node metastasis and predicts postoperative outcome in breast cancer.

@article{Xiao2014AberrantEO,
  title={Aberrant expression of $\delta$-like ligand 4 contributes significantly to axillary lymph node metastasis and predicts postoperative outcome in breast cancer.},
  author={Min Xiao and Shanshan Yang and Xiaoming Ning and Yuanxi Huang},
  journal={Human pathology},
  year={2014},
  volume={45 11},
  pages={
          2302-10
        }
}
DLL4 as a predictor of pelvic lymph node metastasis and a novel prognostic biomarker in patients with early-stage cervical cancer
TLDR
The data indicate that high DLL4 expression predicts pelvic lymph node metastasis and poor survival in cervical cancer and may be a potential clinical diagnostic marker for patients with early-stage cervical cancer.
The Clinicopathological Significance of Jagged1 and DLL4 in Gallbladder Cancer
TLDR
Positive Jagged1 and DLL4 expression is closely correlated with severe clinicopathological characteristics and poor prognosis in patients with SC/ASC and patients with AC.
DLL4 overexpression increases gastric cancer stem/progenitor cell self‐renewal ability and correlates with poor clinical outcome via Notch‐1 signaling pathway activation
TLDR
DLL4 silencing inhibits GCSPC metastatic potential both in vitro and in vivo by impeding Notch‐1 signaling pathway activation, indicating that DLL4 may be a new potential therapeutic target.
Stable silencing of dll4 gene suppresses the growth and metastasis of esophagus cancer cells by attenuating Akt phosphorylation.
TLDR
DLL4 has pathophysiological roles on the progression of esophagus cancer cells, including migration, invasion and apoptosis, which indicated that DLL4 may be considered as a potent therapeutic target for the treatment of malignant esophageal cancer.
Integrative analysis of mutational and transcriptional profiles reveals driver mutations of metastatic breast cancers
TLDR
A novel systems biology approach to identify driver mutations escalating the risk of metastasis based on both exome and RNA sequencing of 78 normal-paired breast cancers, which identifies driver mutations in ADPGK, NUP93, PCGF6, PKP2 and SLC22A5, which are verified to enhance cancer cell migration and prompt metastasis with in vitro experiments.
FKBPL and its peptide derivatives inhibit endocrine therapy resistant cancer stem cells and breast cancer metastasis by downregulating DLL4 and Notch4
TLDR
This study demonstrates, for the first time, the pre-clinical activity of novel systemic anti-cancer therapeutic peptides, ALM201 and AD-01, in the metastatic setting, and highlights their impact on endocrine therapy resistant CSCs; both areas of unmet clinical need.
The Role of DLLs in Cancer: A Novel Therapeutic Target
TLDR
The role of DLLs in cancer is discussed, the emerging DLL-relevant targeting methods to aid future studies are summarized and the current state-of-the-art targeting methods are summarized.
Notch in Human Cancers—A Complex Tale
OTT_A_244860 3881..3901
Medical School of Nanchang University, Nanchang, People’s Republic of China Abstract: Delta-like ligands (DLLs) control Notch signaling. DLL1, DLL3 and DLL4 are frequently deregulated in cancer and

References

SHOWING 1-10 OF 30 REFERENCES
High Expression of Delta-Like Ligand 4 Predicts Poor Prognosis After Curative Resection for Pancreatic Cancer
TLDR
High DLL4 expression is significantly associated with poor prognosis for surgically resected PDAC, advanced tumor stage, and lymph node metastasis, and application of adjuvant therapy targeting D LL4-Notch signaling may improve prognosis.
Elevated DLL4 expression is correlated with VEGF and predicts poor prognosis of nasopharyngeal carcinoma
TLDR
Evidence is provided that high expression of DLL4 serves as an independent predictor of poor prognosis in NPC patients, as evidenced by univariate and multivariate analysis.
Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancer.
TLDR
Dll4 was expressed by endothelium associated with breast cancer cells and was a statistically significant multivariate prognostic factor in univariate and multivariate analyses of overall survival and relapse-free survival.
Predicting Axillary Nodal Positivity in 2282 Patients with Breast Carcinoma
TLDR
Multivariate analysis of patients with invasive cancer identified four factors as independent predictors of axillary lymph node metastases: lymph/vascular invasion, tumor size, nuclear grade, tumor palpability, and ploidy.
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer
TLDR
Endothelial expression of Dll4 is not a prognostic factor, but is significantly associated with VEGF, which may be critical in predicting response to anti-VEGF therapies.
Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
TLDR
It is established that Dll 4 plays a functionally important role in both the tumor and endothelial compartments of ovarian cancer and that targeting Dll4 in combination with anti-VEGF treatment might improve outcomes of ovariancancer treatment.
Lymph node metastasis in breast carcinoma: clinicopathological correlations in 3747 patients.
TLDR
The results of this study reflected the unfortunate presentation of breast cancer patients and some factors could be used as useful guidelines in the management of those patients, including age, tumor size and histologic type of the tumor.
Up-Regulation of Endothelial Delta-like 4 Expression Correlates with Vessel Maturation in Bladder Cancer
TLDR
DLL4 expression is associated with vascular differentiation in bladder cancer; thus, targeting DLL4 may be a novel antiangiogenic therapy.
No common denominator for breast cancer lymph node metastasis
TLDR
The data suggest that breast carcinomas do not use a shared gene set to accomplish lymph node metastasis, and subtle differences in the expression of genes involved in extracellular-matrix organisation and growth factor signalling are detected in individual pairs of matching primary and metastatic tumours.
The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy.
TLDR
The role of HER-2/neu testing for the prediction of response to trastuzumab therapy in breast cancer is presented as well as its potential impact on responses to standard and newer hormonal therapies, cytotoxic chemotherapy, and radiation.
...
...